Acadia Pharmaceuticals (ACAD) Gross Profit (2016 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Gross Profit of $243.3 million for Q1 2026, up 8.64% year-over-year from $223.9 million in Q1 2025, and down 5.62% quarter-over-quarter from $257.8 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Gross Profit (2016 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Gross Profit history runs 11 years deep, the most recent figure standing at $243.3 million for Q1 2026.
- In Q1 2026, Gross Profit rose 8.64% year-over-year to $243.3 million; the TTM figure through Mar 2026 stood at $1.0 billion (up 9.25% YoY), while the FY2025 annual figure was $982.5 million, up 12.16% from the prior year.
- Gross Profit for Q1 2026 stood at $243.3 million, down from $257.8 million in the prior quarter.
- The five-year high for Gross Profit was $257.8 million in Q4 2025, with the low at $112.5 million in Q1 2022.
- The 5-year median for Gross Profit is $213.2 million (2023), against an average of $193.7 million.
- The sharpest annual moves came in 2022 and 2023: Gross Profit gained 0.51% in 2022, then soared 58.98% in 2023.
- Acadia Pharmaceuticals' Gross Profit stood at $134.1 million in 2022, then soared by 58.98% to $213.2 million in 2023, then rose by 11.56% to $237.8 million in 2024, then climbed by 8.4% to $257.8 million in 2025, then declined by 5.62% to $243.3 million in 2026.
- Business Quant data shows ACAD's Gross Profit at $243.3 million in Q1 2026, $257.8 million in Q4 2025, and $257.0 million in Q3 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|